Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WT1 126-134 Peptide Vaccination in AML and MDS
NCT00153582Phase 2Unknown
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Apr 2002
- Modality
- Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of WT1 126-134 peptide in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Generation of T cell response. Status: unknown.
02
Drugs
WT1 126-134 peptide
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00153582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00153582.